Cambridge researchers have injected a first‑ever AI‑designed antigen into human volunteers, sparking hope for a universal defense against future pandemics. In a trial at Southampton and Cambridge, 39 healthy adults aged 18‑50 received the shot with no serious side effects and reported no significant adverse events, showing promising immunogenicity across multiple settings.

The antigen trains the immune system against the Sarbeco coronavirus family, which includes SARS‑CoV‑2, the virus that sparked COVID‑19. Volunteers produced neutralizing antibodies against SARS‑CoV‑2, SARS, and bat‑derived strains that could trigger future outbreaks. Because the design draws on shared viral traits, the vaccine may guard against unseen threats for future infectious agents globally and public.

Unlike reactive vaccines that lag behind evolving strains, this AI‑crafted “super‑antigen” promises a single shot to cover multiple pathogens, including flu and Ebola. Professor Jonathan Heeney, lead of the study, said the approach flips vaccine design from chasing variants to staying ahead. The trial marks a shift toward future‑proof immunization for global health security today.

The next phase will enroll a larger, more diverse cohort to confirm safety and efficacy across demographics. If successful, the AI‑engineered vaccine could reduce the need for annual reformulations and shrink the window between outbreak detection and protection. Cambridge’s work signals a new era where computational biology drives preemptive disease control for public health today.